Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Nov 19;62(21):2000-2007.
doi: 10.1016/j.jacc.2013.05.086. Epub 2013 Jul 31.

Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction

Affiliations
Free article
Comparative Study

Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction

Andrew E Epstein et al. J Am Coll Cardiol. .
Free article

Abstract

Objectives: The aim of this study was to describe usage of the wearable cardioverter-defibrillator (WCD) during mandated waiting periods following myocardial infarction (MI) for patients perceived to be at high risk for sudden cardiac arrest (SCA).

Background: Current device guidelines and insurance coverage require waiting periods of either 40 days or 3 months before implanting a cardioverter-defibrillator post-myocardial infarction (MI), depending on whether or not acute revascularization was undertaken.

Methods: We assessed characteristics of and outcomes for patients who had a WCD prescribed in the first 3 months post-MI. The WCD medical order registry was searched for patients who were coded as having had a "recent MI with ejection fraction ≤35%" or given an International Classification of Diseases, Ninth Revision 410.xx diagnostic code (acute MI), and then matched to device-recorded data.

Results: Between September 2005 and July 2011, 8,453 unique patients (age 62.7 ± 12.7 years, 73% male) matched study criteria. A total of 133 patients (1.6%) received 309 appropriate shocks. Of these patients, 91% were resuscitated from a ventricular arrhythmia. For shocked patients, the left ventricular ejection fraction (LVEF) was ≤30% in 106, 30% to 35% in 17, >36% in 8, and not reported in 2 patients. Of the 38% of patients not revascularized, 84% had a LVEF ≤30%; of the 62% of patients revascularized, 77% had a LVEF ≤30%. The median time from the index MI to WCD therapy was 16 days. Of the treated patients, 75% received treatment in the first month, and 96% within the first 3 months of use. Shock success resulting in survival was 84% in nonrevascularized and 95% in revascularized patients.

Conclusions: During the 40-day and 3-month waiting periods in patients post-MI, the WCD successfully treated SCA in 1.4%, and the risk was highest in the first month of WCD use. The WCD may benefit individual patients selected for high risk of SCA early post-MI.

Keywords: AED; ICD; LVEF; MVT; OMT; PMVT; SCA; SCD; SSDMF; Social Security Death Master File; VF; VFl; WCD; automated external defibrillator; defibrillation; implantable cardioverter-defibrillator; left ventricular ejection fraction; monomorphic ventricular tachycardia; optimized medical therapy; polymorphic ventricular tachycardia; resuscitation; sudden cardiac arrest; sudden cardiac death; ventricular fibrillation; ventricular flutter; wearable cardioverter-defibrillator.

PubMed Disclaimer

Comment in

Publication types

LinkOut - more resources